Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Mitsubishi Tanabe Pharma gets US rights to AnGes' Phase III Collategene; later expands rights

Executive Summary

Mitsubishi Tanabe Pharma Corp. licensed exclusive US marketing rights to AnGes MG Inc.’s (gene therapy) Collategene (beperminogene perplasmid), a DNA plasmid with hepatocyte growth factor gene, for peripheral arterial diseases (PADs).
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies